Signed written informed consent approved by the reviewing Ethics Committee (EC).
Adult patients (≥18 years of age, no upper limit).
Eligible to receive neratinib for extended adjuvant treatment as per prescribing information in China, diagnosed with HER2 overexpressing/amplified early-stage breast cancer regardless of hormone receptor (HR) status and clinical/radiological assessed to be negative for recurrences or metastatic disease.
You may not be if
Presence of any contraindication with regard to the neratinib treatment.
Current or upcoming participation in an interventional clinical trial. (Investigational treatment within four weeks of enrolment).
Clareo Health | Treatment Patterns of Neratinib in HER2+ EBC in China
